The role of erenumab in the treatment of migraine

Therapeutic Advances in Neurological Disorders
Anna P AndreouGiorgio Lambru

Abstract

Calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) have been the first class of specifically developed preventive treatments for migraine. Clinical trials data suggest superiority of the CGRP mAbs to placebo in terms of prevention of migraine symptoms, migraine-specific quality of life and headache related disability. Treatment-related side effects overall did not differ significantly from placebo and discontinuation rate due to side effects has been low across the clinical trials, perhaps in view of their peripheral mode of action. Along with their route and frequency of administration, these novel class of drugs may constitute an improvement compared with the established arsenal of migraine treatments. Erenumab is a fully human antibody and the only mAb acting on the CGRP pathway by blocking its receptor. It is the first of the CGRP mAb class approved by the US Food and Drug Administration (May 2018) and the European Medicines Agency (July 2018). Erenumab exists in two different doses (70 mg and 140 mg) and it is administered with monthly subcutaneous injections. This review summarises erenumab pharmacological characteristics, clinical trials data, focusing on the potential role of this treatment in clinical ...Continue Reading

References

Jan 1, 1987·International Archives of Allergy and Applied Immunology·J C Foreman
Apr 1, 1987·British Medical Bulletin·J C Foreman
Jun 1, 1989·Endocrinologia Japonica·K TakahashiN Sasano
Dec 1, 1987·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·L EdvinssonR Uddman
Jan 3, 1985·Nature·S D BrainI MacIntyre
Dec 1, 1981·Cephalalgia : an International Journal of Headache·L Edvinsson, R Uddman
Jan 1, 1984·The Journal of Physiology·R Couture, A C Cuello
Jan 1, 1995·Cephalalgia : an International Journal of Headache·L Edvinsson, P J Goadsby
Apr 1, 1996·The Journal of Investigative Dermatology·H A BullP M Dowd
Jun 5, 1997·European Journal of Pharmacology·D J WilliamsonR J Hargreaves
Jun 1, 1997·Cephalalgia : an International Journal of Headache·D J WilliamsonS L Shepheard
Jul 21, 1999·Journal of the Autonomic Nervous System·J TajtiL Edvinsson
Jun 26, 2001·Cephalalgia : an International Journal of Headache·J TajtiL Edvinsson
Oct 24, 2001·Biology of Reproduction·T J BivalacquaW J Hellstrom
Feb 16, 2002·The Journal of Biological Chemistry·John J MalleeStefanie A Kane
Mar 12, 2004·The New England Journal of Medicine·Jes OlesenUNKNOWN BIBN 4096 BS Clinical Proof of Concept Study Group
Jul 9, 2004·British Journal of Pharmacology·Robin James StorerPeter J Goadsby
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Nov 13, 2004·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Thorsten SchinkeMichael Amling
Jan 18, 2006·Headache·Jaime L BellamyPaul L Durham
Jan 28, 2006·European Journal of Pharmacology·Wenxia ChaiRegien G Schoemaker

❮ Previous
Next ❯

Citations

Apr 27, 2021·Frontiers in Neurology·Marcello SilvestroAntonio Russo
Nov 4, 2021·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Xing WangChao You

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved